Arcutis Announces Pricing of $150 Million Public Offering
February 28, 2024 23:30 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the pricing of its underwritten public offering of common stock.
Arcutis Announces Proposed Public Offering
February 28, 2024 16:10 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
February 28, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis and Sato today announced that the companies have entered into a strategic collaboration and licensing agreement for topical roflumilast in Japan.
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024 05:50 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter and year ended December 31, 2023, and provided a business update.
Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results
February 16, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27, 2024.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference
January 31, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that Arcutis management will participate in the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference.
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
January 29, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that JAAD published positive results from the pivotal Phase 3 STRATUM trial evaluating ZORYVE (roflumilast) foam, 0.3%.
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
January 22, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the launch of ZORYVE® (roflumilast) topical foam, 0.3%, in the United States for the treatment of seborrheic dermatitis
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
January 14, 2024 04:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced a new subgroup analysis in adults and adolescents with seborrheic dermatitis from STRATUM study